Ivonib (ivitinib) combined with chemotherapy is a new option for some patients with acute myeloid leukemia

Ivonib (ivitinib), as a new type of targeted drug, has shown significant efficacy in the treatment of acute myeloid leukemia (AML) in recent years. Especially for patients with IDH1 and IDH2 mutations, ivonib provides a new treatment strategy.

In a pivotalPhase II clinical trial, ivonib was effective in IDH1mutatedAML It demonstrated significant anti-tumor activity in patients, with an overall response rate of 40%, of which 22% achieved complete response. This shows that ivonib is a very effective treatment for this group of patients. At the same time, a large phase III clinical trial also further confirmed the efficacy of ivonib in patients with IDH2 mutated AML. The study included more than 700 patients, and the results showed that the overall survival and disease progression-free survival of the ivonib group were significantly better than those of the traditional chemotherapy group.

The safety of ivonib has been widely recognized in clinical trials. Most patients tolerate treatment, and adverse effects are relatively mild. This makes ivonib a relatively safe and effective treatment option. Compared with traditional chemotherapy drugs, ivosidenib has fewer side effects, which can help improve patients' quality of life and treatment compliance.

Avosidenib can be used in combination with other anti-cancer drugs, including traditional chemotherapy drugs. This combined treatment regimen can further improve treatment effects and bring better prognosis to patients. For example, in the AGILE Phase 3 trial, the combination of ivonib and the chemotherapy drug azacitidine showed significant efficacy, effectively reducing the risk of events (treatment failure, relapse after remission, death).